{"id":900789,"date":"2025-10-27T16:45:42","date_gmt":"2025-10-27T20:45:42","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/universal-health-services-inc-announces-financial-results-for-the-three-and-nine-month-periods-ended-september-30-2025-increases-2025-full-year-operating-results-forecast-and-announces-1-5-billio\/"},"modified":"2025-10-27T16:45:42","modified_gmt":"2025-10-27T20:45:42","slug":"universal-health-services-inc-announces-financial-results-for-the-three-and-nine-month-periods-ended-september-30-2025-increases-2025-full-year-operating-results-forecast-and-announces-1-5-billio","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/universal-health-services-inc-announces-financial-results-for-the-three-and-nine-month-periods-ended-september-30-2025-increases-2025-full-year-operating-results-forecast-and-announces-1-5-billio\/","title":{"rendered":"UNIVERSAL HEALTH SERVICES, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2025, INCREASES 2025 FULL YEAR OPERATING RESULTS FORECAST AND ANNOUNCES $1.5 BILLION INCREASE TO STOCK REPURCHASE PROGRAM AUTHORIZATION"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n Consolidated Results of Operations, As Reported and As Adjusted\u00a0 \u2013 Three-month periods ended September 30, 2025<\/span> and 2024:<\/u>
\n <\/i>\n <\/p>\n

\n
\n KING OF PRUSSIA, Pa.<\/span>
\n <\/span>, Oct. 27, 2025<\/span><\/span> \/PRNewswire\/ — Universal Health Services, Inc. (NYSE: UHS) announced today that its reported net income attributable to UHS was $373.0 million<\/span>, or $5.86<\/span> per diluted share, during the third quarter of 2025, as compared to $258.7 million<\/span>, or $3.80<\/span> per diluted share, during the third quarter of 2024. Net revenues increased by 13.4% to $4.495 billion<\/span> during the third quarter of 2025, as compared to $3.963 billion<\/span> during the third quarter of 2024.<\/p>\n

As reflected on the Schedule of Non-GAAP Supplemental Information (“Supplemental Schedule”), our adjusted net income attributable to UHS during the third quarter of 2025 was $362.3 million<\/span>, or $5.69<\/span> per diluted share, as compared to $252.5 million<\/span>, or $3.71<\/span> per diluted share, during the third quarter of 2024.\u00a0<\/p>\n

Included in our reported and adjusted net income attributable to UHS during the third quarter of 2025 were the following items which were\u00a0not included in our 2025 operating results forecast, as previously disclosed on July 28, 2025<\/span>: (i) $90 million<\/span> of pre-tax reimbursements (net of related provider taxes), covering the period of October 1, 2024<\/span> through September 30, 2025<\/span>, in connection with a recently approved Medicaid state directed payment program in Washington, D.C.<\/span>, and; (ii) a $35 million<\/span> pre-tax charge incurred to increase our reserves for self-insured professional and general liabilities resulting from unfavorable claims’ trends.<\/p>\n

As reflected on the Supplemental Schedule, included in our reported results during the third quarter of 2025 were: (i) an unrealized after-tax gain of $10.0 million<\/span>, or $.16<\/span> per diluted share ($13.1 million<\/span> pre-tax), resulting from an increase in the market value of certain equity securities (included in “Other (income) expense, net”), and; (ii) a favorable net after-tax impact of $0.6 million<\/span>, or $.01<\/span> per diluted share, resulting from the net tax benefit recorded in connection with “ASU 2016-09”, Compensation \u2013 Stock Compensation: Improvements to Employee Share-Based Payment Accounting, net of the impact of executive compensation limitations pursuant to IRC section 162(m).\u00a0\u00a0\u00a0\u00a0<\/p>\n

As reflected on the Supplemental Schedule, included in our reported results during the third quarter of 2024 were: (i) an unrealized after-tax gain of $2.3 million<\/span>, or $.03<\/span> per diluted share ($3.0 million<\/span> pre-tax), resulting from an increase in the market value of certain equity securities, and; (ii) a favorable after-tax impact of $3.9 million<\/span>, or $.06<\/span> per diluted share, resulting from the tax benefit recorded in connection ASU 2016-09. \u00a0\u00a0\u00a0\u00a0<\/p>\n

As calculated on the attached Supplemental Schedule, our earnings before interest, taxes, depreciation & amortization (“EBITDA net of NCI”, NCI is net income attributable to noncontrolling interests), was $684.2 million<\/span> during the third quarter of 2025, as compared to $528.6 million<\/span> during the third quarter of 2024. Our adjusted earnings before interest, taxes, depreciation & amortization (“Adjusted EBITDA net of NCI”), which excludes the impact of other (income) expense, net, was $670.6 million<\/span> during the third quarter of 2025, as compared to $526.5 million<\/span> during the third quarter of 2024.<\/p>\n

\n
\n Consolidated Results of Operations, As Reported and As Adjusted\u00a0 \u2013 Nine-month periods ended September 30, 2025<\/span> and 2024:<\/u>
\n <\/i>\n <\/p>\n

Reported net income attributable to UHS was $1.043 billion<\/span>, or $16.07<\/span> per diluted share, during the first nine months of 2025, as compared to $809.7 million<\/span>, or $11.88<\/span> per diluted share, during the comparable period of 2024. Net revenues increased by 9.9% to $12.879 billion<\/span> during the first nine months of 2025, as compared to $11.714 billion<\/span> during the comparable period of 2024.<\/p>\n

As reflected on the Supplemental Schedule, our adjusted net income attributable to UHS during the first nine months of 2025 was $1.030 billion<\/span>, or $15.87<\/span> per diluted share, as compared to $798.2 million<\/span>, or $11.71<\/span> per diluted share, during the comparable period of 2024.\u00a0<\/p>\n

As reflected on the Supplemental Schedule, included in our reported results during the first nine months of 2025 were: (i) an unrealized after-tax gain of $11.3 million<\/span>, or $.17<\/span> per diluted share ($14.7 million<\/span> pre-tax), resulting from an increase in the market value of certain equity securities, and; (ii) a favorable net after-tax impact of $1.9 million<\/span>, or $.03<\/span> per diluted share, resulting from the net tax benefit recorded in connection with ASU 2016-09. \u00a0\u00a0\u00a0\u00a0<\/p>\n

As reflected on the Supplemental Schedule, included in our reported results during the first nine months of 2024 were: (i) an unrealized after-tax loss of $4.0 million<\/span>, or $.06<\/span> per diluted share ($5.3 million<\/span> pre-tax), resulting from a decrease in the market value of certain equity securities, and; (ii) a favorable after-tax impact of $15.5 million<\/span>, or $.23<\/span> per diluted share, resulting from the tax benefit recorded in connection with ASU 2016-09.\u00a0<\/p>\n

As calculated on the attached Supplemental Schedule, our EBITDA net of NCI, was $1.939 billion<\/span> during the first nine months of 2025, as compared to $1.628 billion<\/span> during the comparable period of 2024. Our Adjusted EBITDA net of NCI, was $1.912 billion<\/span> during the first nine months of 2025, as compared to $1.631 billion<\/span> during the comparable period of 2024.<\/p>\n

\n
\n Acute Care Services \u2013 Three and nine-month periods ended September 30, 2025<\/span> and 2024:<\/u>
\n <\/i>\n <\/p>\n

During the third quarter of 2025, at our acute care hospitals owned during both periods (“same facility basis”), adjusted admissions (adjusted for outpatient activity) increased by 2.0% while adjusted patient days increased by 0.4%, as compared to the third quarter of 2024. At these facilities, during the third quarter of 2025, net revenue per adjusted admission increased by 9.8% while net revenue per adjusted patient day increased by 11.5%, as compared to the third quarter of 2024. Net revenues generated from our acute care services, on a same facility basis, increased by 12.8% during the third quarter of 2025, as compared to the third quarter of 2024.<\/p>\n

During the nine-month period ended September 30, 2025<\/span>, at our acute care hospitals on a same facility basis, adjusted admissions increased by 2.1% while adjusted patient days increased by 0.6%, as compared to the comparable period of 2024. At these facilities, during the first nine months of 2025, net revenue per adjusted admission increased by 5.4% while net revenue per adjusted patient day increased by 7.0%, as compared to the comparable period of 2024. Net revenues generated from our acute care services, on a same facility basis, increased by 9.1% during the first nine months of 2025, as compared to the comparable period of 2024.<\/p>\n

\n
\n Behavioral Health Care Services \u2013 Three and nine-month periods ended September 30, 2025<\/span> and 2024:<\/u>
\n <\/i>\n <\/p>\n

During the third quarter of 2025, at our behavioral health care facilities on a same facility basis, adjusted admissions increased by 0.5% while adjusted patient days increased by 1.3%, as compared to the third quarter of 2024. At these facilities, during the third quarter of 2025, net revenue per adjusted admission increased by 8.8% and net revenue per adjusted patient day increased by 7.9%, as compared to the third quarter of 2024. Net revenues generated from our behavioral health care services, on a same facility basis, increased by 9.3% during the third quarter of 2025, as compared to the third quarter of 2024.<\/p>\n

During the first nine months of 2025, at our behavioral health care facilities on a same facility basis, adjusted admissions decreased by 0.2% while adjusted patient days increased by 0.7%, as compared to the comparable period of 2024. At these facilities, during the first nine months of 2025, net revenue per adjusted admission increased by 8.2% and net revenue per adjusted patient day increased by 7.2%, as compared to the comparable period of 2024. Net revenues generated from our behavioral health care services, on a same facility basis, increased by 7.9% during the first nine months of 2025, as compared to the comparable period of 2024.<\/p>\n

\n
\n Net Cash Provided by Operating Activities and Liquidity:<\/u>
\n <\/i>\n <\/p>\n

\n Net Cash Provided by Operating Activities:<\/i>\n <\/p>\n

During the nine-month period ended September 30, 2025<\/span>, our net cash provided by operating activities was $1.290 billion<\/span> as compared to $1.409 billion<\/span> during the first nine months of 2024. The $119 million<\/span> net decrease in our net cash provided by operating activities consisted of: (i) a favorable change of $257 million<\/span> resulting from an increase in net income plus\/minus depreciation and amortization expense, stock-based compensation expense and gains\/losses on sales of assets and businesses, offset by; (ii) an unfavorable change of $306 million<\/span> in accounts receivable (which includes the above-mentioned $90 million<\/span> of net reimbursements recorded during the third quarter of 2025, which we expect will be received during the fourth quarter of 2025, in connection with a recently approved Medicaid state directed payment program in Washington, D.C.<\/span>); (iii) an unfavorable change of $41 million<\/span> in payments made in settlement of self-insurance claims, net of commercial insurance reimbursements, and; (iv) an unfavorable change of $28 million<\/span> in accrued and deferred income taxes. \u00a0<\/p>\n

\n Liquidity:<\/i>\n <\/p>\n

As of September 30, 2025<\/span>, we had $965 million<\/span> of aggregate available borrowing capacity pursuant to our $1.3 billion<\/span> revolving credit facility, net of outstanding borrowings and letters of credit.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n

\n
\n Increased Authorization to Stock Repurchase Program:<\/u>
\n <\/i>\n <\/p>\n

On October 27, 2025<\/span>, our Board of Directors authorized a $1.5 billion<\/span> increase to our stock repurchase program. Pursuant to this program, which including today’s increased authorization has a current aggregate available repurchase authorization of $1.759 billion<\/span>, shares of our Class B Common Stock may be repurchased, from time to time as conditions allow, on the open market or in negotiated private transactions.\u00a0<\/p>\n

Pursuant to this program, during the third quarter of 2025, we have repurchased 1.315 million shares at an aggregate cost of approximately $234.3 million<\/span> (average price of approximately $178<\/span> per share). During the first nine months of 2025, we have repurchased 3.190 million shares at an aggregate cost of approximately $565.8 million<\/span> (average price of approximately $177<\/span> per share).<\/p>\n

\n
\n Revised 2025 Operating Results Forecast:<\/u>
\n <\/i>\n <\/p>\n

Based upon the operating trends and financial results experienced during the first nine months of 2025, as well as the recent approval of a new Medicaid supplemental payment program in Washington, D.C.<\/span>, as indicated on the Revised Forecast<\/i> table below, we are increasing our operating results forecast range for consolidated net revenues, adjusted earnings before interest, taxes, depreciation & amortization, and the impacts of other income\/expense and net income attributable to noncontrolling interests (“Adjusted EBITDA, net of NCI”), and adjusted net income attributable to UHS per diluted share (“Adjusted EPS-diluted”) for the year ended December 31, 2025<\/span>.<\/p>\n

The tables below include our revised full year 2025 operating results forecast, as well as our previously revised 2025 operating results forecast which was disclosed on July 28, 2025<\/span>.<\/p>\n

\n\n\n\n\n\n\n\n\n
\n \n <\/td>\n\n

\n
\n Revised Forecast<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n \n <\/td>\n\n

\n
\n Previous Forecast<\/b>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n \n <\/td>\n\n

\n
\n For the Year Ended<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n \n <\/td>\n\n

\n
\n For the Year Ended<\/b>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n \n <\/td>\n\n

\n
\n December 31, 2025<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n \n <\/td>\n\n

\n
\n December 31, 2025<\/b>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n \n <\/td>\n\n

\n
\n Low<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n
\n High<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n \n <\/td>\n\n

\n
\n Low<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n
\n High<\/b>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Net revenues<\/span>\n <\/p>\n<\/td>\n

\n

\n $17.306 billion<\/span>\n <\/p>\n<\/td>\n

\n

\n $17.445 billion<\/span>\n <\/p>\n<\/td>\n

\n \n <\/td>\n\n

\n $17.096 billion<\/span>\n <\/p>\n<\/td>\n

\n

\n $17.312 billion<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Adjusted EBITDA, net of NCI<\/span>\n <\/p>\n<\/td>\n

\n

\n $2.569 billion<\/span>\n <\/p>\n<\/td>\n

\n

\n $2.619 billion<\/span>\n <\/p>\n<\/td>\n

\n \n <\/td>\n\n

\n $2.458 billion<\/span>\n <\/p>\n<\/td>\n

\n

\n $2.543 billion<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Adjusted EPS \u2013 diluted<\/span>\n <\/p>\n<\/td>\n

\n

\n $21.50 per share<\/span>\n <\/p>\n<\/td>\n

\n

\n $22.10 per share<\/span>\n <\/p>\n<\/td>\n

\n \n <\/td>\n\n

\n $20.00 per share<\/span>\n <\/p>\n<\/td>\n

\n

\n $21.00 per share<\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n